A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase 3 Study of Intra-Articular Administration of an Allogeneic Human Placental Tissue Particulate (PTP-001) for the Treatment of Knee Osteoarthritis
Latest Information Update: 03 Nov 2025
At a glance
- Drugs PTP-001 (Primary)
- Indications Osteoarthritis
- Focus Registrational; Therapeutic Use
- Acronyms MOTION
- Sponsors Doron Therapeutics
Most Recent Events
- 03 Nov 2025 New trial record
- 16 Oct 2025 Planned number of patients changed from 260 to 300.
- 16 Oct 2025 According to Doron Therapeutics media release, the first patient has been dosed.